Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia - Patients to Be Treated with RP-L102 under “Process B” Incorporating Higher Cell Doses, ...
RP-L201 has received FDA Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track and Orphan Drug designations; Rocket eligible for Priority Review Voucher, if RP-L201 is approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback